Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adelaide A Hebert

Showing results (81-90 of 150) with videos related to

Pageof 15
Sort By:
The Journal of Clinical and Aesthetic Dermatology|May 31, 2021
Once-daily Dapsone 7.5% Gel for the Treatment of Acne Vulgaris in Preadolescent Patients: A Phase IV, Open-label, 12-week StudyAngela Yen Moore, Edward L Lain, Amy McMichael, et al.
Pediatric Dermatology|March 10, 2020
Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension studyAdelaide A Hebert, Dee Anna Glaser, Lawrence Green, et al.
Dermatology and Therapy|September 22, 2021
Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic DermatitisBob Geng, Adelaide A Hebert, Liza Takiya, et al.
Dermatology and Therapy|August 11, 2021
Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic DermatitisBob Geng, Adelaide A Hebert, Liza Takiya, et al.
Journal of Drugs in Dermatology : JDD|January 11, 2024
Integrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne VulgarisLawrence F Eichenfield, Linda Stein Gold, Jenny Han, et al.
Journal of Drugs in Dermatology : JDD|August 9, 2023
Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne VulgarisLawrence F Eichenfield, Adelaide A Hebert, Linda Stein Gold, et al.
The Journal of Pediatrics|May 22, 2008
MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled studyMark Boguniewicz, Joshua A Zeichner, Lawrence F Eichenfield, et al.
Journal of the American Academy of Dermatology|October 7, 2019
Efficacy and tolerability of an investigational nitric oxide-releasing topical gel in patients with molluscum contagiosum: A randomized clinical trialAdelaide A Hebert, Elaine C Siegfried, Todd Durham, et al.
Pediatric Dermatology|June 11, 2015
A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary HyperhidrosisDee Anna Glaser, David M Pariser, Adelaide A Hebert, et al.
Journal of Drugs in Dermatology : JDD|March 11, 2026
Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert PanelApril W Armstrong, Yvonne Nong, Christopher G Bunick, et al.
Pageof 15

Showing results (81-90 of 150) with videos related to

Sort By:
Pageof 15
The Journal of Clinical and Aesthetic Dermatology|May 31, 2021
Once-daily Dapsone 7.5% Gel for the Treatment of Acne Vulgaris in Preadolescent Patients: A Phase IV, Open-label, 12-week StudyAngela Yen Moore, Edward L Lain, Amy McMichael, et al.
Pediatric Dermatology|March 10, 2020
Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension studyAdelaide A Hebert, Dee Anna Glaser, Lawrence Green, et al.
Dermatology and Therapy|September 22, 2021
Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic DermatitisBob Geng, Adelaide A Hebert, Liza Takiya, et al.
Dermatology and Therapy|August 11, 2021
Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic DermatitisBob Geng, Adelaide A Hebert, Liza Takiya, et al.
Journal of Drugs in Dermatology : JDD|January 11, 2024
Integrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne VulgarisLawrence F Eichenfield, Linda Stein Gold, Jenny Han, et al.
Journal of Drugs in Dermatology : JDD|August 9, 2023
Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne VulgarisLawrence F Eichenfield, Adelaide A Hebert, Linda Stein Gold, et al.
The Journal of Pediatrics|May 22, 2008
MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled studyMark Boguniewicz, Joshua A Zeichner, Lawrence F Eichenfield, et al.
Journal of the American Academy of Dermatology|October 7, 2019
Efficacy and tolerability of an investigational nitric oxide-releasing topical gel in patients with molluscum contagiosum: A randomized clinical trialAdelaide A Hebert, Elaine C Siegfried, Todd Durham, et al.
Pediatric Dermatology|June 11, 2015
A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary HyperhidrosisDee Anna Glaser, David M Pariser, Adelaide A Hebert, et al.
Journal of Drugs in Dermatology : JDD|March 11, 2026
Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert PanelApril W Armstrong, Yvonne Nong, Christopher G Bunick, et al.
Pageof 15